Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
Eli Lilly's next-generation obesity drug, retatrutide, successfully completed its Phase 3 trial, demonstrating weight-loss results comparable to bariatric surgery.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 51.8%.
Get high-impact news instantly
Top stories with score 8/10+ delivered to your Telegram in real time. Free.
Join Telegram channel